Dr. Vandita Kakkar is an Associate Professor of Pharmaceutics at the University Institute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh, with over 14 years of experience in teaching and research. Her research primarily focuses on enhancing the bioavailability of phytopharmaceuticals using nanoparticle technology through oral and topical delivery routes. She is also actively involved in scaling up nanoparticle production from laboratory to pilot scale, combating antimicrobial resistance, and developing targeted drug delivery systems for cancer therapy. She has filed 8 national and 4 international patents, with 4 patents granted. Her scholarly contributions include over 70 national and international research and review publications, with an h-index of 23 and more than 3000 citations, along with 14 book chapters in reputed international publications. She has secured competitive research funding exceeding ₹2.35 crores from agencies including UGC, DST, ICMR, BIRAC, Panjab University, and the Commonwealth. With 2 years of industrial experience, she has also successfully transferred technology to Hi Tech Innovations Ltd. and serves as a consultant to several pharmaceutical companies. Recognized for her scientific contributions, Dr Kakkar has received multiple awards and accolades. Most recently, she has been included in Stanford University’s prestigious “Top 2% Scientists” global list for 2025.

Dr. Nan Fang is the Chair, CEO, and Co-founder of Singleron Biotechnologies, a pioneering life science tools company specializing in single-cell multi-omics technologies. Founded in 2018, Singleron has rapidly become one of the leading single cell multi-omics solution providers and expanded its global presence with operations in Germany, the United States, China, and Singapore, offering comprehensive solutions for research, clinical applications, and drug development. Prior to founding Singleron, Dr. Fang had over ten years’ experience in product development, commercialisation, team management and corporate strategy with global biotech firms (in Germany, USA, China). Her past roles include: Deputy General Manager at Novogene (responsible for novel NGS service solutions) EY. Associate Director of Global R&D at QIAGEN in Germany, where she founded & led the product development team for the Universal NGS Market Program, and participated in business‐area management. She is inventor on more than 20 patents/patent applications. Dr. Fang holds a Ph.D. in Immunology from the University of Iowa, an MBA from Julius-Maximilians-Universität Würzburg, and an Bachelor of Science in Biology from the University of Science & Technology of China.